Curaleaf Holdings, Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Cannabis Operations and Non-Cannabis Operations segments. The Cannabis Operations segment includes the production and sale of cannabis via retail and wholesale channels. The Non-Cannabis Operations segment provides professional services including cultivation, processing and retail know-how and back office administration, intellectual property licensing, real estate leasing services and lending facilities to medical and adult-use cannabis licensees under management service agreements. The company was founded on November 13, 2014 and is headquartered in New York, NY.

WAKEFIELD, Mass., March 12, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that Joseph Bayern, Curaleaf Chief Executive Officer, will be participating in the Cannabis State of the Industry Panel presentation at the Roth Capital Partners Virtual 33rd Annual Conference for investors on Tuesday, March 16, 2021 at 2:00 pm ET.

Curaleaf Announces Participation in Roth Capital Partners Virtual 33rd Annual Conference

Curaleaf enters the European market with the acquisition of EMMAC Life Sciences.

Curaleaf: Global Cannabis Domination

WAKEFIELD, Mass., March 11, 2021 /PRNewswire/ -- A new survey conducted by Siena College Research Institute on behalf of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, finds 57% of New Yorkers favor a faster rollout of legalized cannabis through the expansion of the current medical market compared to legalization proposals that could take 18 months or longer.

Survey Finds A Majority Of New York Voters Support Accelerated Rollout Of Legalized Cannabis

Chairman Boris Jordan expects change, now that Democrats control the White House and Congress.

Curaleaf Is Upbeat About Cannabis Reform. Here's Why.

The multistate cannabis operator has tremendous growth opportunities both in the U.S. and in Europe.

Curaleaf's Q4 Growth Was Impressive, but 2021 Should Be Even Better

FastForward Innovations Ltd (LON:FFWD) said it has agreed to sell its entire interest in cannabis firm EMMAC Life Sciences as part of a takeover of the investee by North American cannabis consumer products group Curaleaf Holdings Inc (CSE:CURA) (OTCQX:CURLF). The AIM-listed firm said it will sell its 6.7mln shares in EMMAC as well as a £750,000 convertible loan note for around £5.04mln, and that it expects to record a profit from the sale of around £1.9mln compared to the September 2020 carrying value of the equity and cost price of the convertible loan note, and an overall return of 1.86 times its original investment.

FastForward Innovations agrees to sell interest in cannabis firm EMMAC Life Sciences

Curaleaf Holdings' (CURLF) CEO Joe Bayern on Q4 2020 Results - Earnings Call Transcript

Acquisitions helped propel revenue higher, and are sure to continue doing so.

Curaleaf Posts 205% Q4 Revenue Growth, Announces $286 Million Deal for European Peer

CURLF reported 205% revenue growth in its latest quarter. The company has fortified its balance sheet with a $240 million cash infusion from recent equity offerings.

Curaleaf Is Firing On All Cylinders: Blockbuster Earnings, Largest USA Cannabis Company

Cannabis company Curaleaf Holdings Inc. (OTCQX:CURLF) is looking to expand to Europe via M&A. The Wakefield, Massachusetts-based company announced Tuesday that it will acquire one of Europe's largest cannabis companies, EMMAC Life Sciences, for approximately $286 million in cash and stock.

Curaleaf Wields M&A To Tap European Market, Agrees To Buy EMMAC For $286M

WAKEFIELD, Mass., March 9, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today reported its financial and operating results for the fourth quarter and year ended December 31, 2020.

Curaleaf Reports Record Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results

WAKEFIELD, Mass., March 9, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that it has signed a definitive agreement to acquire EMMAC Life Sciences Limited ("EMMAC"), the largest vertically integrated independent cannabis company in Europe for base consideration of approximately US$286 million to be paid 85% in Curaleaf subordinate voting shares and 15% in cash.

Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited - Europe's Leading Independent Cannabis Company

Aphria

Canopy Growth

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Trulieve Cannabis Corp.

Tilray Brands

Alpha Trader Talks Cannabis Investing With Todd Harrison (Podcast)

With Q4 results coming this week, this cannabis stock gives investors multiple reasons to buy and hold it.

Ahead of Earnings, Curaleaf's CFO Says Fiscal 2020 Will End on a High Note

Shares of U.S. multi-state cannabis operator Curaleaf Holdings Inc. (OTCQX: CURLF) traded lower by 3.6% on Thursday morning, but one analyst has high hopes for the company's fourth-quarter earnings report next week. The Analyst: On Thursday, Roth Capital Partners analyst Scott Fortune reiterated his Buy rating and $20 price target for Curaleaf.

Analyst Previews Curaleaf Earnings: 'Bellwether Of The U.S. Cannabis Industry'

GW Pharmaceuticals

Jazz Pharmaceuticals

MedMen Enterprises Inc.

OrganiGram Holdings Inc.

SNDL Inc.

Each of these cannabis stocks blazed higher by between 20% and 208% last month.

The 10 Best Marijuana Stocks in February

The cannabis producer has been one of the hottest buys in the industry over the past year.

Is Curaleaf Stock a Buy?

Cronos Group

Aurora Cannabis

HEXO Corp

CRON stock stands to gain from state-level cannabis legalization as well as from speculation around federal legalization. The post Cronos Group and Other Cannabis Stocks Could See Higher Highs appeared first on InvestorPlace.

Cronos Group and Other Cannabis Stocks Could See Higher Highs

Constellation Brands

These five marijuana stocks are for careful, conservative investors. They each have safe financial traits for those who like to play it safe.

5 Marijuana Stocks for the Conservative Investor

The sale and consumption of recreational weed are now permitted in the populous state.

New Jersey Marijuana Legalization Measures Signed Into Law

U.S. companies are overlooked by many investors. But any state and federal legalization favors them over Canadian rivals, fund managers say.

Cannabis Watch: If you want to get rich with marijuana stocks, you need to know the crucial difference between U.S. and Canadian companies

Canadian cannabis stocks have surged in 2021 and a few of them have exhibited irrational exuberance such as Tilray and Sundial. U.S. cannabis stocks continue to trade at a substantial discount despite possessing significantly stronger fundamentals.

Tilray, Sundial May Be In A Bubble But This Group Remains Attractive

The U.S. MSO sector is dominated by the Big 4 players and Curaleaf is the biggest player in terms of scale and market capitalization. Curaleaf shares have lagged Trulieve and Green Thumb in both 2021 so far and the last year; we think the underperformance will continue.

Curaleaf: The Priciest But Not The Strongest Of The Big 4 MSOs

These marijuana stocks weathered the novel coronavirus storm and are likely to push through with greater gains in 2021. The post 7 Marijuana Stocks Ready To Surge Again appeared first on InvestorPlace.

7 Marijuana Stocks Ready To Surge Again

Altria

The sector is hot again on the heels of two large deals.

News for Curaleaf Holdings, Inc. Stock (CURLF)